Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl undecenoyl leucinate is a synthetic small molecule primarily used as an active ingredient in skin whitening creams. It acts as an antagonist of alpha-melanocyte-stimulating hormone (α-MSH) by competitively binding to the melanocortin 1 receptor (MC1R), thereby inhibiting the activation of adenylate cyclase and protein kinase A pathways. This leads to downregulation of melanogenic gene expression—including MITF, tyrosinase, TRP-1, and TRP-2—and ultimately suppresses melanin synthesis and tyrosinase activity. The compound is noted for its efficacy in reducing pigmentation and has demonstrated a favorable safety profile with no significant cytotoxicity or irritation reported in healthy volunteers. It also exhibits anti-inflammatory effects against environmental stimuli such as UV exposure[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl undecenoyl leucinate.